ArticleBlood advances2023
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.
Abstract read
In one paragraph
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.Blood advances · 2025Trial
- Combining drugs that bypass p53 to treat TP53-mutated leukemias.Blood advances · 2025Article
- A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC.Journal of hematology & oncology · 2024Review
- cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory.Bioinformatics (Oxford, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors.
Maximilian StahlDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Omar Abdel-WahabDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Andrew H WeiPeter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID 0000-0002-7514-3298
Michael R SavonaDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-3763-5504
Mina L XuDepartments of Pathology & Laboratory Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT.
Zhuoer XieDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.ORCID 0000-0003-1266-9804
Justin TaylorSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.ORCID 0000-0003-4407-6325
Daniel StarczynowskiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Guillermo F SanzHematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.ORCID 0000-0002-2767-8191
David A SallmanDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
Valeria SantiniMDS Unit, AOUC, University of Florence, Florence, Italy.ORCID 0000-0002-5439-2172
Gail J RobozWeill Cornell Medicine and The New York Presbyterian Hospital, New York, NY.ORCID 0000-0002-0384-3658
Mrinal M PatnaikDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.ORCID 0000-0001-6998-662X
Eric PadronDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
Olatoyosi OdenikeThe University of Chicago, Chicago, IL.
Aziz NazhaDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Stephen D NimerSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.
Ravindra MajetiDivision of Hematology, Department of Medicine, Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Richard F LittleNational Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-4091-1699
Steven GoreNational Cancer Institute, National Institutes of Health, Bethesda, MD.
Alan F ListPrecision BioSciences, Inc, Durham, NC.
Vijay KutchrooEvergrande Center for Immunologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA.
Rami S KomrokjiDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.ORCID 0000-0002-1876-5269
Tae Kon KimDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-5182-3870
Nina KimNational Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-1809-0417
Christopher S HouriganLaboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-6189-8067
Robert P HasserjianDepartment of Pathology, Massachusetts General Hospital, Boston, MA.
Stephanie HaleneSection of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT.ORCID 0000-0002-2737-9810
Elizabeth A GriffithsRoswell Park Comprehensive Cancer Center, Buffalo, NY.ORCID 0000-0002-0288-8248
Peter L GreenbergDivision of Hematology, Department of Medicine, Cancer Institute, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-7615-9443
Maria FigueroaSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.
Pierre FenauxHôpital Saint Louis, Paris, France.
Fabio EfficaceItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Amy E DeZernThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MD.
Matteo G Della PortaHumanitas Clinical and Research Center & Humanitas University, Department of Biomedical Sciences, Milan, Italy.
Naval G DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7103-373X
Jane E ChurpekDepartment of Hematology, Oncology, and Palliative Care, Carbone Cancer Center, The University of Wisconsin-Madison, Madison, WI.
Hetty E CarrawayLeukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0001-5241-3614
Andrew M BrunnerCenter for Leukemia, Massachusetts General Hospital, Boston, MA.
Uma BorateDivision of Hematology, Department of Internal Medicine, James Cancer Center, Ohio State University, Columbus, OH.
John M BennettHematopathology Division, Departments of Pathology and Medicine, University of Rochester Medical Center, Rochester, NY.
Rafael BejarDivision of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, CA.ORCID 0000-0002-5603-4598
Jacqueline BoultwoodBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-4330-2928
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8980-3202
Jan Philipp BewersdorfDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Uwe PlatzbeckerDepartment of Hematology and Cellular Therapy, Medical Clinic and Policlinic I, Leipzig University Hospital, Leipzig, Germany.ORCID 0000-0003-1863-3239
David P SteensmaNovartis Institutes of BioMedical Research.ORCID 0000-0001-5130-9284
Mikkael A SekeresSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.
Rena J BucksteinOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
Amer M ZeidanSection of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MDetection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0MYale Cooperative Hematology Specialized Core CenterU54DK106857 · NIDDK · YALE UNIVERSITY · PI JOHN HWA, Diane S Krause · 2015 to 2026
$9.7MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NIDDK NIH HHS U54 DK106857
Abstract
PubMed holds no abstract for this paper.
Indexed as
Myelodysplastic SyndromesChromosome AberrationsHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.